Ubiquinol clinical brief
Ubiquinol
Dossier liveAmitochondrial_cofactor - strongest use in mitochondrial_dysfunction
Evidence strength
High confidence
19 meta-analyses - 110 RCTs - 186 tracked studies
What it is for
Heart failure adjunctive therapy (NYHA II-IV)
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Human linked
HbA1c
Glycemic control
Decrease
Grade A
HOMA-IR
Glycemic control
Decrease
Grade B
LDL-C
Lipid response
Decrease
Grade A
Top caution
Drug interaction
Ubiquinol shares a naphthoquinone ring system structurally analogous to vitamin K; theoretical competition with vitamin K-dependent coagulation factor activation (factors II, VII, IX, X); may reduce anticoagulant efficacy in some patients; effect is inconsistent across case reports
Evidence index
87
Authored product-registry confidence score
Meta-analyses
19
Pooled human evidence
RCTs
110
Randomized clinical trials
Tracked studies
186
Studies currently mapped to this dossier
Executive summary
Immediate brief
Ubiquinol is a mitochondrial_cofactor sourced from endogenous_biosynthesis_and_dietary with its clearest current use in Heart failure adjunctive therapy (NYHA II-IV).
High confidence human evidence supports the brief, anchored by 186 tracked studies, 19 meta-analyses, 110 RCTs and the most reliable movement in HbA1c, HOMA-IR, LDL-C.
Ubiquinol shares a naphthoquinone ring system structurally analogous to vitamin K; theoretical competition with vitamin K-dependent coagulation factor activation (factors II, VII, IX, X); may reduce anticoagulant efficacy in some patients; effect is inconsistent across case reports Ubiquinol shares a naphthoquinone ring system structurally analogous to vitamin K; theoretical competition with vitamin K-dependent coagulation factor activation (factors II, VII, IX, X); may reduce anticoagulant efficacy in some patients; effect is inconsistent across case reports Anti-inflammatory claims most valid for chronic cardiovascular, metabolic, and autoimmune disease; do not extrapolate to acute critical illness, burns, or sepsis based on current evidence
Anchor decision
Heart failure adjunctive therapy (NYHA II-IV)
Best current human use case
Confidence
High confidence
19 meta-analyses - 110 RCTs - 186 tracked studies
Read next
Drug interaction
Pressure-test the lead caution before acting.
Reading guide
How to use this brief
1. Orient
Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.
2. Pressure-test
Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.
3. Operationalize
Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.
Major warning
Dpregnancy
Anti-inflammatory claims most valid for chronic cardiovascular, metabolic, and autoimmune disease; do not extrapolate to acute critical illness, burns, or sepsis based on current evidence
Overview
Clinical posture
Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.
Primary signal
Mechanism summary
Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.
Co-primary
Safety summary
These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.
Supporting context
Evidence scope
Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.
Generalizability
ReviewAnti-inflammatory claims most valid for chronic cardiovascular, metabolic, and autoimmune disease; do not extrapolate to acute critical illness, burns, or sepsis based on current evidence
Evidence scope
ReviewStrongest adjunctive evidence in heart failure is for mortality reduction; patients with NYHA II-III most studied; LVEF improvement should not be primary expectation
Evidence scope
ReviewDistinguish formulations when presenting evidence; acknowledge that most large-scale heart failure evidence is from ubiquinone studies; ubiquinol-specific HF evidence base is smaller
Generalizability
ReviewAntioxidant claims require population context; do not claim universal oxidative stress reduction; note null results in critically ill
Synergies
Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.
Ubiquinol + D-ribose
Pierce 2018 RCT protocol registered a 2×2 factorial design testing ubiquinol and/or D-ribose for HFpEF symptom burden reduction (n planned; results in pierce_2022).
Research unknowns
These are the open questions that still keep the compound from reading like a closed case.